Recruiting
Early Phase 1

Buprenorphine

Sponsor:

Medical University of South Carolina

Code:

NCT07421102

Conditions

Opioid Use Disorder

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

strategy of mailing buprenorphine

Study Details

Brief summary:

This pilot study evaluates the feasibility, acceptability, and preliminary effectiveness of mailing buprenorphine to individuals with opioid use disorder (OUD) following medical hospitalization. The intervention aims to improve retention in treatment by overcoming barriers such as transportation and pharmacy access.

Conditions

Opioid Use Disorder

Study ID

NCT07421102

Start date

Apr 8, 2026

Status verified date

Apr, 2026

Completion date

Mar, 2027

Anticipated

Primary completion date

Jan, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Age ≥ 18
  • English-speaking
  • Diagnosed with OUD and initiated on buprenorphine during hospitalization
  • Discharging to a South Carolina address with a stable mailbox
  • Access to phone or computer

Exclusion Criteria:

  • Active psychosis or suicidal ideation
  • Severe medical or neurocognitive impairment
  • Pending incarceration

Study Design

Enrollment

20 participants

Anticipated

Intervention Model

Single group

Primary purpose

Other

Interventions and Outcome Measures

Arms

other: Mailed Medications

There is no comparison arm. This pilot study evaluates the feasibility of mailing medications to patients.

Interventions

strategy of mailing buprenorphine

This study examines the feasibility and preliminary effectiveness of mailing buprenorphine to overcome barriers such as transportation to obtaining buprenorphine from a pharmacy.

Primary outcome measure

  • Feasibility (successful receipt) [ Time Frame: From enrollment to the end of the study at 6 months ]
  • Successful receipt [ Time Frame: From enrollment to the end of study at 6 months. ]
  • Retention in treatment [ Time Frame: time of study enrollment to end of study at 6 months ]

Central Contacts and Locations

Locations

Medical University of South Carolina

Recruiting

Charleston, South Carolina, United States, 29425

Contacts

Primary Investigator, MD

843-792-0686smithall@musc.edu

Research Coordinator, BS

schneidh@musc.edu

Principal Investigator:

Allison Smith, MD

More Information

Sponsor

Medical University of South Carolina

Last update posted

Jul 30, 2026

Last verified

Apr, 2026

Keywords

  • mailing buprenorphine
  • transitions of care
  • opioid use disorder
  • barriers to buprenorphine

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Medical University of South Carolina on 2026-07-30.